Effect of nitazoxanide on albendazole pharmacokinetics in cerebrospinal fluid and plasma in rats.
Background:Although albendazole is the drug-of-choice for the treatment of neurocysticercosis, its efficacy is limited due to its low bioavailability. An alternative for optimizing pharmacological treatment is through drug combinations.In vitrostudies have shown that nitazoxanide and tizoxanide (the active metabolite of nitazoxanide) exhibit cysticidal activity and that the combination of tizoxanide with albendazole sulfoxide (the active metabolite of albendazole) produced an additive effect.Objectives:(1) To assess the concentration profile of tizoxanide in plasma and in cerebrospinal fluid; and (2) to evaluate the influence of nitazoxanide on the pharmacokinetics of albendazole in plasma and in cerebrospinal fluid.Methods:Two different studies were conducted. In study 1, 10 male Sprague-Dawley rats received a single oral dose of 7.5 mg/kg of nitazoxanide and serial blood and cerebrospinal fluid samples were collected over a period of 4 h. In study 2, 38 healthy male Sprague-Dawley rats were randomly divided into two groups: one of these received a single dose of albendazole (15 mg/kg) and, in the other group, albendazole (15 mg/kg) was co-administered with nitazoxanide (7.5 mg/kg). Plasma and cerebrospinal fluid samples were collected from 0 to 16 h after administration. Albendazole sulfoxide and tizoxanide levels were assayed by using HPLC or LC/MS techniques.Results:In study 1, tizoxanide reached a maximum plasma concentration of 244.42 ± 31.98 ng/mL at 0.25 h; however, in cerebrospinal fluid, this could be detected only at 0.5 h, and levels were below the quantification limit (10 ng/mL). These data indicate low permeation of tizoxanide into the blood brain barrier. In study 2, Cmax, the area under the curve, and the mean residence time of albendazole sulfoxide in plasma and cerebrospinal fluid were not affected by co-administration with nitazoxanide.Conclusion:The results of the present study indicate that in rats at the applied doses, tizoxanide does not permeate into the cerebrospinal fluid. Furthermore, nitazoxanide does not appear to alter significantly the pharmacokinetics of albendazole in plasma or in cerebrospinal fluid.
Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.
María Isabel
MI
Ruiz-Olmedo
Laboratorio de Neuropsicofarmacología, Instituto Nacional de Neurología y Neurocirugía, Mexico City 14269, Mexico.
Iliana
I
González-Hernández
Laboratorio de Neuropsicofarmacología, Instituto Nacional de Neurología y Neurocirugía, Mexico City 14269, Mexico.
Francisca
F
Palomares-Alonso
Laboratorio de Fisiología de la Formación Reticular, Instituto Nacional de Neurología y Neurocirugía, Mexico City 14269, Mexico.
Javier
J
Franco-Pérez
Departamento de Farmacología, Centro de Investigación y de Estudios Avanzados, Instituto Politécnico Nacional, Mexico City 07360, Mexico.
María de Lourdes
ML
González F
Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico; Laboratorio de Neuropsicofarmacología, Instituto Nacional de Neurología y Neurocirugía, Mexico City 14269, Mexico.
Helgi
H
Jung-Cook
Albendazole; Albendazole sulfoxide; Cerebrospinal fluid; Nitazoxanide; Pharmacokinetics; Tizoxanide